One of the thriving medical company development companies is Lantheus Holdings and GE Healthcare. In view of the risk of Coronary Artery Disease (CAD) among the population, the PET imaging agent called flurpiridaz F 18 has been legalised for improved and effective diagnosis of CAD.
The newly developed agent can mainly be attached to the mitochondrial complex 1. The flurpiridaz agent F 18 is known as a myocardial perfusion imaging agent for research on positron emission tomography. The GE healthcare has the full right to market the cardiac imaging agent globally in accordance with the developmental agreement. In order to estimate the safety and efficiency of the PET imaging agent, the company reports that a second Phase III clinical trial is being conducted.
Lantheus Holdings will also co-publicise the PET imaging agent in the United States as well as contributing to the marketing and development of the imaging agent. In terms of development and marketing, the two companies await the success of the new cardiac PET imaging agent.
The company is pleased to expand and extend its long-standing business relationship with GE Healthcare using the annual supply agreement, according to the CEO Mary Anne Heino, Lantheus Holdings.
Now, companies plan to sell the product by using their previous $5 million and the $60 million that they receive when the regulatory and sales target has been cleared.
The company’s main priority is to expand and strengthen its foothold in the nuclear medicines market, according to Emmanuel Ligner, GE Healthcare Core Imaging General Manager. GE Healthcare wants to offer patients and clinics the best method for the improval of the treatment of coronary artery disease for customer-friendly and low-effect diagnosis.
Under the terms of the two business agreements, Lantheus plans to extend its contract to GE healthcare by the end of December 2020 and continue to sell Gallium-67, Xenon-133 and TechneLite Xenon Xe 133 Gas.
In the coming years, the companies therefore plan to strengthen their business relations by developing and marketing products.